|
1
|
Hutchinson L: Gynecological cancer: True
progress in ovarian cancer or just the tip of the iceberg? Nat Rev
Clin Oncol. 9:652012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jha A, Khan Y, Mehdi M, Karim MR, Mehmood
Q, Zappa A, Rebholz-Schuhmann D and Sahay R: Towards precision
medicine: Discovering novel gynecological cancer biomarkers and
pathways using linked data. J Biomed Semantics. 8:402017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li H, Zhang W, Sun X, Chen J, Li Y, Niu C,
Xu B and Zhang Y: Overexpression of kinesin family member 20A is
associated with unfavorable clinical outcome and tumor progression
in epithelial ovarian cancer. Cancer Manag Res. 10:3433–3450. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang S and Chen X: Identification of
potential biomarkers in cervical cancer with combined public mRNA
and miRNA expression microarray data analysis. Oncol Lett.
16:5200–5208. 2018.PubMed/NCBI
|
|
5
|
Krishnan P, Ghosh S, Wang B, Heyns M,
Graham K, Mackey JR, Kovalchuk O and Damaraju S: Profiling of small
nucleolar RNAs by next generation sequencing: Potential new players
for breast cancer prognosis. PLoS One. 11:e01626222016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yadav SS, Li J, Lavery HJ, Yadav KK and
Tewari AK: Next-generation sequencing technology in prostate cancer
diagnosis, prognosis, and personalized treatment. Urol Oncol.
33:267 e1–e13. 2015. View Article : Google Scholar
|
|
7
|
Weisenberger DJ: Characterizing DNA
methylation alterations from the cancer genome atlas. J Clin
Invest. 124:17–23. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cancer Genome Atlas Research Network, ;
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sanchez-Vega F, Mina M, Armenia J, Chatila
WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia
S, et al: Oncogenic signaling pathways in the cancer genome atlas.
Cell. 173:321–337 e10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Berger AC, Korkut A, Kanchi RS, Hegde AM,
Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, et al: A
Comprehensive pan-cancer molecular study of gynecologic and breast
cancers. Cancer Cell. 33:690–705 e9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song J, Ye A, Jiang E, Yin X, Chen Z, Bai
G, Zhou Y and Liu J: Reconstruction and analysis of the aberrant
lncRNA-miRNA-mRNA network based on competitive endogenous RNA in
CESC. J Cell Biochem. 119:6665–6673. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hagemann IS, Cole LL, Cosin JA, Gress DM,
Mutch DG and Olawaiye AB: Controversies in gynecologic cancer
staging: An AJCC cancer staging manual, eighth edition perspective.
AJSP Rev Rep. 23:118–128. 2018.
|
|
14
|
de Hoon MJ, Imoto S, Nolan J and Miyano S:
Open source clustering software. Bioinformatics. 20:1453–1454.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Page RD: TreeViewGlasgow University;
Glasgow, UK: 2001
|
|
16
|
Huang DW, Sherman BT, Tan Q, Kir J, Liu D,
Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC and Lempicki RA:
DAVID Bioinformatics Resources: Expanded annotation database and
novel algorithms to better extract biology from large gene lists.
Nucleic Acids Res. 35((Web Server Issue)): W169–W175. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
The Gene Ontology Consortium, . The gene
ontology resource: 20 years and still GOing strong. Nucleic Acids
Res. 47(D1): D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abu-Shawer O, Abu-Shawer M, Hirmas N,
Alhouri A, Massad A, Alsibai B, Sultan H, Hammo H, Souleiman M,
Shebli Y and Al-Hussaini M: Hematologic markers of distant
metastases and poor prognosis in gynecological cancers. BMC Cancer.
19:1412019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Coscia F, Lengyel E, Duraiswamy J,
Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K,
Montag A, Yamada SD, et al: Multi-level proteomics identifies CT45
as a chemosensitivity mediator and immunotherapy target in ovarian
cancer. Cell. 175:159–170 e16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
George J, Alsop K, Etemadmoghadam D,
Hondow H, Mikeska T, Dobrovic A, deFazio A; Australian Ovarian
Cancer Study Group, ; Smyth GK, Levine DA, et al: Nonequivalent
gene expression and copy number alterations in high-grade serous
ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res.
19:3474–3484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McLaughlin JR, Rosen B, Moody J, Pal T,
Fan I, Shaw PA, Risch HA, Sellers TA, Sun P and Narod SA: Long-term
ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
J Natl Cancer Inst. 105:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen L, Yao Y, Sun L, Zhou J, Miao M, Luo
S, Deng G, Li J, Wang J and Tang J: Snail driving alternative
splicing of CD44 by ESRP1 enhances invasion and migration in
epithelial ovarian cancer. Cell Physiol Biochem. 43:2489–2504.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pusapati RV, Daemen A, Wilson C, Sandoval
W, Gao M, Haley B, Baudy AR, Hatzivassiliou G, Evangelista M and
Settleman J: mTORC1-dependent metabolic reprogramming underlies
escape from glycolysis addiction in cancer cells. Cancer Cell.
29:548–562. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu S, Yin H, Ji H, Zhu J and Ma R:
Overexpression of TRIM44 is an independent marker for predicting
poor prognosis in epithelial ovarian cancer. Exp Ther Med.
16:3034–3040. 2018.PubMed/NCBI
|
|
26
|
Kim SI, Lee JW, Lee N, Lee M, Kim HS,
Chung HH, Kim JW, Park NH, Song YS and Seo JS: LYL1 gene
amplification predicts poor survival of patients with uterine
corpus endometrial carcinoma: Analysis of the Cancer genome atlas
data. BMC Cancer. 18:4942018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li LX, Zhou JX, Calvet JP, Godwin AK,
Jensen RA and Li X: Lysine methyltransferase SMYD2 promotes triple
negative breast cancer progression. Cell Death Dis. 9:3262018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zuo SR, Zuo XC, He Y, Fang WJ, Wang CJ,
Zou H, Chen P, Huang LF, Huang LH, Xiang H and Liu SK: Positive
expression of SMYD2 is associated with poor prognosis in patients
with primary hepatocellular carcinoma. J Cancer. 9:321–330. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reynoird N, Mazur PK, Stellfeld T, Flores
NM, Lofgren SM, Carlson SM, Brambilla E, Hainaut P, Kaznowska EB,
Arrowsmith CH, et al: Coordination of stress signals by the lysine
methyltransferase SMYD2 promotes pancreatic cancer. Genes Dev.
30:772–785. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zodro E, Jaroszewski M, Ida A, Wrzesiński
T, Kwias Z, Bluyssen H and Wesoly J: FUT11 as a potential biomarker
of clear cell renal cell carcinoma progression based on
meta-analysis of gene expression data. Tumour Biol. 35:2607–2617.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang K, Zhou Y, Li G, Wen X, Kou Y, Yu J,
He H, Zhao Q, Xue F, Wang J and Zhao X: MMP8 and MMP9 gene
polymorphisms were associated with breast cancer risk in a Chinese
Han population. Sci Rep. 8:134222018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wieczorek E, Reszka E, Wasowicz W,
Grzegorczyk A, Konecki T, Sosnowski M and Jablonowski Z: MMP7 and
MMP8 genetic polymorphisms in bladder cancer patients. Cent
European J Urol. 66:405–410. 2014.PubMed/NCBI
|
|
33
|
Dębniak T, Jakubowska A, Serrano-Fernández
P, Kurzawski G, Cybulski C, Chauhan SR, Laxton RC, Maleszka R,
Lubinski J and Ye S: Association of MMP8 gene variation with an
increased risk of malignant melanoma. Melanoma Res. 21:464–468.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Palavalli LH, Prickett TD, Wunderlich JR,
Wei X, Burrell AS, Porter-Gill P, Davis S, Wang C, Cronin JC,
Agrawal NS, et al: Analysis of the matrix metalloproteinase family
reveals that MMP8 is often mutated in melanoma. Nat Genet.
41:518–520. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun Q, Zhang Y, Su J, Li T and Jiang Y:
Role of hydroxysteroid dehydrogenase-like 2 (HSDL2) in human
ovarian cancer. Med Sci Monit. 24:3997–4008. 2018. View Article : Google Scholar : PubMed/NCBI
|
